About 900,000 Australian women could access cheaper treatment for uncomplicated urinary tract infections (UTIs) and hormonal contraception under an expanded federal pharmacy trial due to begin in February 2027.
Health Minister Mark Butler and Minister for Women Katy Gallagher announced on Monday, 26 October, that the 12-month trial would be opened beyond concession card holders to eligible women more broadly. The government will cover pharmacist consultation fees of up to $38 per visit. Where prescription medicines are needed, they will be priced at Pharmaceutical Benefits Scheme (PBS)-equivalent rates: currently up to $25 for general patients and $7.70 for concession card holders.
The trial will allow participating pharmacies to assess and treat uncomplicated UTIs and provide initiation or repeat supplies of selected hormonal contraceptives. Access to starting hormonal contraception through a pharmacist will depend on the rules in the relevant state or territory. The services are intended to be delivered by trained pharmacists under the program’s clinical requirements.
The federal government says the expanded trial could benefit around 900,000 women and is part of its broader women’s health package. The program is designed to make care easier to access through local pharmacies, including for women who face delays or costs when trying to book a general practitioner appointment.
The Pharmacy Guild of Australia welcomed the expansion and called it a landmark reform. The Guild said consultations would be available at eligible participating pharmacies, with private clinical consultation rooms and trained pharmacists. The trial is expected to run for 12 months, with its effectiveness and safety to be evaluated before any decision about its future.
However, the Royal Australian College of General Practitioners has raised concerns about whether pharmacy consultations will be suitable for women whose symptoms are more complex. RACGP president Michael Wright warned that an incorrect diagnosis could lead to unnecessary antibiotics while another cause of symptoms is missed or treatment is delayed.
The trial is limited to uncomplicated UTIs and specified hormonal contraception services; it does not mean every urinary symptom or contraceptive need can be managed at a pharmacy. Women with severe, unusual or persistent symptoms may require medical assessment, and pharmacists must work within the applicable clinical protocols and state or territory prescribing rules.
The government has said the trial will help assess how the pharmacy model works in practice, including assessment, referral and follow-up. Further implementation details will be provided as the start date approaches.
